In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2017 Completed Trials: Status Quo Or No?

Executive Summary

Trialtrove data provides window onto the landscape of industry-sponsored clinical trials completed during 2017.

You may also be interested in...

Steps On The Long Road To Therapies For Uncontrolled Asthma

Turn back time: oncology trials are getting shorter

It is widely accepted in the biopharmaceutical industry that clinical trial protocols are growing in complexity; many in the business bewail that the duration of trials is increasing, with patient enrollment a frequently-cited problem in clinical development.

2010 Scrip 100 - Little change in win, place or show

When examining the competitiveness of company pipelines, and the extent of a company's R&D commitment, it is arguably more relevant to consider the number of drug projects as reflected by clinical trials activity as opposed to the overall number of drugs in the pipeline. Clinical trial activity was assessed over the 12-month period from September 2008 to August 2009, using data from TrialTrove where trial start dates were disclosed in the public domain.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts